Biotech and Big Pharma alike are taking outsourcing to new heights in 2008, according to IDC's Health Industry Insights report. This year everything from R&D to clinical trials and manufacturing will be outsourced in growing volumes to countries like Singapore, India and China, says the new forecast. Singapore in particular was lauded for its huge investments in the drug development and manufacturing field and a reputation for strong intellectual property provisions.
- see this release [1]
- here's the report [2] from the Birmingham Business Journal
Related Articles:
Chinese outsourcing poses new risks. Report [3]
AstraZeneca to outsource manufacturing. Report [4]
Eli Lilly to outsource half of research by 2010. Report [5]
Links:
[1] http://www.fiercebiotech.com/press-releases/health-industry-insights-predicts-mega-it-investment-business-intelligence-2008
[2] http://www.bizjournals.com/birmingham/stories/2008/01/14/daily10.html?b=1200286800^1576281
[3] http://www.fiercepharma.com/story/chinese-outsourcing-poses-new-risks/2007-12-06
[4] http://www.fiercepharma.com/story/astrazeneca-outsource-manufacturing/2007-09-17
[5] http://www.fiercebiotech.com/story/eli-lilly-outsource-half-research-2010/2007-12-17